Format

Send to

Choose Destination
Cancer Lett. 2016 Jan 28;370(2):324-31. doi: 10.1016/j.canlet.2015.11.005. Epub 2015 Nov 12.

Circulating tumor DNA identified by targeted sequencing in advanced-stage non-small cell lung cancer patients.

Author information

1
Department of Lung Cancer Surgery, Tianjin Medical University General Hospital, Tianjin, China.
2
San Valley Biotechnology Incorporated, Beijing, China.
3
Department of Thoracic Surgery, Tianjin Chest Hospital, Tianjin, China.
4
Norris Comprehensive Cancer Center, Department of Molecular Microbiology and Immunology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
5
Norris Comprehensive Cancer Center, Department of Molecular Microbiology and Immunology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. Electronic address: siyichen@usc.edu.
6
Department of Lung Cancer Surgery, Tianjin Medical University General Hospital, Tianjin, China. Electronic address: huntercj2004@yahoo.com.

Abstract

Non-small cell lung cancers (NSCLC) have unique mutation patterns, and some of these mutations may be used to predict prognosis or guide patient treatment. Mutation profiling before and during treatment often requires repeated tumor biopsies, which is not always possible. Recently, cell-free, circulating tumor DNA (ctDNA) isolated from blood plasma has been shown to contain genetic mutations representative of those found in the primary tumor tissue DNA (tDNA), and these samples can readily be obtained using non-invasive techniques. However, there are still no standardized methods to identify mutations in ctDNA. In the current study, we used a targeted sequencing approach with a semi-conductor based next-generation sequencing (NGS) platform to identify gene mutations in matched tDNA and ctDNA samples from 42 advanced-stage NSCLC patients from China. We identified driver mutations in matched tDNA and ctDNA in EGFR, KRAS, PIK3CA, and TP53, with an overall concordance of 76%. In conclusion, targeted sequencing of plasma ctDNA may be a feasible option for clinical monitoring of NSCLC in the near future.

KEYWORDS:

Circulating tumor DNA; Ion PGM/AmpliSeq cancer panel; NSCLC; Next generation sequencing; Targeted sequencing

PMID:
26582655
DOI:
10.1016/j.canlet.2015.11.005
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center